SAS Output

26-MAY-2017 18:10

LUNG ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1400-SCCA,Adv, Biomarker Master 1 Y 1 Specimen Submission   1281 525 187 112 37 7 07/08/2014 439 217
            1281 525 187 112 37 7      
 
    2 Y 17 S1400G   21 21 21 18 9 4      
        2 S1400A   160 0 0 0 0 0 07/08/2014    
        3 S1400B   54 18 1 0 0 0      
        4 S1400C   88 5 0 0 0 0      
        5 S1400D   93 26 0 0 0 0      
        6 S1400E   16 0 0 0 0 0      
        7 S1400I   540 366 144 80 22 8      
            972 436 166 98 31 12      
 
    3 P 10 S1400I   6 6 2 0 0 0      
        18 S1400G   4 4 4 4 1 0      
        8 S1400B   1 1 0 0 0 0 07/08/2014    
            11 11 6 4 1 0      
 
  S1400A-Non-Match: MEDI4736 1 N 1 MEDI4736 140 78 0 0 0 0 0 07/31/2014 4 5
        2 Docetaxel   38 0 0 0 0 0      
            116 0 0 0 0 0      
 
    2 Y 3 MEDI4736 140 3 3 2 1 0 0 07/31/2014    
            3 3 2 1 0 0      
 
  S1400G-HRRD: Talazoparib (BMN 673) 1 Y 1 Talazoparib (BMN 673) 60 12 12 12 12 6 0 03/03/2017 431 207
            12 12 12 12 6 0      
 
  S1400I-Non-Match: Nivo + Ipi vs Nivo 1 Y 1 Nivolumab + Ipilimumab 350 99 75 31 12 4 1 12/29/2015 439 216
        2 Nivolumab   101 80 31 17 6 1      
            200 155 62 29 10 2      
 
  S1403-Adv,EGFR-mt,Afatinib+/-Cetuximab 1 Y 1 AFATINIB + CETUXIMAB 605 57 33 19 14 6 0 05/07/2015 223 87
        2 AFATINIB   54 30 17 6 5 1      
            111 63 36 20 11 1      
 
  S1507-NSCLC, Adv, Kras Mut, Trametinib + Docetaxel 1 Y 1 Trametinib + Docetaxel 53 30 30 25 13 8 4 10/05/2016 164 78
            30 30 25 13 8 4      
 
  8811-NSCLC, Stage III,ChemoRT+ABT-888 1 Y 5 RT+Pac+Carbo+blinded drug 132 11 11 10 7 2 1 01/24/2013 108 36
        6 RT+Pac+Carbo+blinded drug   10 10 8 4 1 0      
            21 21 18 11 3 1      
 
    2 Y 8 Pac + Carbo + blinded drug 132 6 6 6 5 3 1 01/24/2013    
            6 6 6 5 3 1      
 
Yes A081105-ALCHEMIST1, EGFR mut, Erlotinib 1 E Total Registrations   22 13 10 7 2 0 04/01/2015   246
            22 13 10 7 2 0      
 
  A151216-ALCHEMIST0 - screening 1 E Total Registrations   286 169 93 45 7 1 12/16/2014 459 247
            286 169 93 45 7 1      
 
  C140503-NSCL, Lobect v Sublobar resect 1 E Total Registrations   17 4 0 0 0 0 07/02/2008 104 56
            17 4 0 0 0 0      
 
    2 E Total Registrations   27 3 0 0 0 0 07/02/2008    
            27 3 0 0 0 0      
 
  C30610-SCLC, Thoracic RT 1 E Total Registrations   50 0 0 0 0 0 05/14/2008 240 111
            50 0 0 0 0 0      
 
  E4512-ALCHEMIST2, ALK mut, Crizotinib 1 E Total Registrations   3 1 0 0 0 0 02/29/2016 463 244
            3 1 0 0 0 0      
 
  NRGCC003-SCLC, PCI or HA-PCI 1 E Total Registrations   1 1 0 0 0 0 10/20/2016 318 128
            1 1 0 0 0 0      
 
    2 E Total Registrations   1 1 0 0 0 0 10/20/2016    
            1 1 0 0 0 0      
 
  R1306-NSCLC,Adv,ALK/EGFR,TargetAgents 1 E Total Registrations   8 0 0 0 0 0 03/12/2014 144 67
            8 0 0 0 0 0      
 
No A151216-ALCHEMIST0 - screening 0 E Total Registrations   295 171 97 48 11 1 12/16/2014 459 247
            295 171 97 48 11 1      
 
  C30607-NSCL,Adv Main Sunitinib v Placbo 1 E Total Registrations   2 0 0 0 0 0 09/25/2013    
            2 0 0 0 0 0      
 
  EA5142-ALCHEMIST3, Non-match, Nivolumab 1 E Total Registrations   12 12 7 5 2 0 08/03/2016 433 224
            12 12 7 5 2 0